LOS ANGELES , Aug. 21, 2024 /PRNewswire/ -- Partillion Bioscience Corporation ("Partillion"), a life science tools company, announced the launch of its Early Access Program for the Nanovial Multicell Assays. This innovative platform is designed to transform the study of cell-to-cell interactions by allowing researchers to co-localize cells within Nanovials, hydrogel nanoliter compartments, offering unprecedented insights into cellular behavior in biologically-relevant context.
The Early Access Program provides select academic and biopharmaceutical partners with the opportunity to integrate this cutting-edge technology into their research workflows, enabling them to explore how a cell's secretions affect a co-localized target cell with higher precision and scalability than ever before. Unlocking New Possibilities in Antibody Discovery and Beyond Nanovial Multicell Assays are particularly well-suited for overcoming key challenges in antibody discovery. Traditional in vitro and in vivo antibody discovery methods are limited to targets that can be produced in a soluble recombinant form, restricting the ability to screen for function-inducing antibodies that require target expression on cell membranes.
This is a significant obstacle when targeting proteins that maintain their physiological structure only in their native cellular context, such as G-protein coupled receptors (GPCRs) and immune checkpoint proteins. A recent pre-print, titled "Function-First Plasma Cell-Based Antibody.